article thumbnail

Valneva’s Lyme disease vaccine faces final clinical test in a sparse landscape

Pharmaceutical Technology

Lyme disease is also known as borreliosis, which refers to the borrelia bacteria that cause the condition. A vaccine called Lymerix , then manufactured by SmithKline Beecham, was approved in the US in 1998 but was quickly withdrawn in 2002 due to insufficient custo mer demand. It is currently treated with antibiotics.

article thumbnail

Lumen Bioscience’s LMN-201 secures FDA fast track status to treat CDI

Pharmaceutical Technology

An investigational orally delivered biologic drug, LMN-201 is a cocktail of four therapeutic proteins that act synergistically to neutralise the C difficile bacterium and the toxin. It is compatible with standard-of-care antibiotics. Pivotal trials on LMN-201 are expected to commence in 2023.

Bacterium 130
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Leading freeze-drying systems suppliers for the pharmaceutical industry

Pharmaceutical Technology

Pharmaceutical and biotechnology industries widely use freeze-drying systems to protect vaccines, antibodies, antibiotics such as penicillin, blood plasma, proteins, enzymes, hormones, viruses, and bacteria from heat and minimise their biological activity.

article thumbnail

Biologics – The Next Step in Revolutionary Medication

Roots Analysis

With the increased interest and gradual shift of investment from small molecule drugs to biologics and the establishment of several biologics manufacturing companies / biologics CMOs, more than 250 biologic therapies and vaccines have been developed, globally.

article thumbnail

Pfizer to Slash COVID-19 Vaccine Manufacturing Time by Almost 50 Percent

XTalks

Amidst growing global shortages of COVID-19 vaccine supplies, inaugural (by way of authorizations/approvals) COVID-19 vaccine maker Pfizer is addressing the issue by working to cut the manufacturing time of its vaccine by almost half. coli bacteria. The bacteria are grown in large vats, with the process taking two weeks.

article thumbnail

BioIVT acquires Cypex to boost portfolio  

Drug Discovery World

Provider to the life sciences industry BioIVT has acquired enzymes manufacturer Cypex in a bid to enhance its product portfolio. . Based in Dundee, Cypex manufactures recombinant xenobiotic metabolizing enzymes with its product portfolio covering a wide range of proteins involved in drug metabolism. .

article thumbnail

Advances in cell line development

Drug Discovery World

Cell line development is an essential underpinning of the drug development process, enabling teams to test, optimise and manufacture therapeutics at a commercial scale. For instance, bacteria and yeast cell lines are easier to cultivate compared with mammalian cell lines, requiring less maintenance for the medium they are grown in.